Key result
Baseline chronic kidney disease in patients undergoing TAVR was associated with significantly higher mortality compared to non-CKD patients (10% vs. 4.1%; P=0.04%).
Why the study?
Chronic kidney disease is common in patients undergoing TAVR, but reported outcome studies on the association of baseline CKD and mortality are currently limited.
Observational (n=499)
Yes
Background: Chronic kidney disease (CKD) is a common comorbid condition in patients undergoing transcatheter aortic valve replacement (TAVR). Reported outcome studies on the association of baseline CKD and mortality is currently limited. Objectives: To determine the prevalence of chronic kidney disease in patients undergoing TAVR and analyse their overall procedural outcomes. Methods: This retrospective observational study was conducted at 43 publicly funded hospitals in Hong Kong. Severe aortic stenosis patients undergoing TAVR between the years 2010 and 2019 were enroled in the study. Two groups were identified according to the presence of baseline chronic kidney disease. Results: A total of 499 patients (228, 58.6% men) were enroled in the study. Baseline hypertension was more prevalent in patients with CKD (82.8%; P =0.003). As for primary end-points, mortality rates of CKD patients were significantly higher compared to non-CKD patients (10% vs. 4.1%; P =0.04%). Gout and hypertension were found to be significantly associated with CRF. Patients with gout were nearly six times more likely to have CRF than those without gout (odds ratio = 5.96, 95% CI = 3.12–11.29, P <0.001). Patients with hypertension had three times the likelihood of having CRF compared to those without hypertension (odds ratio=2.83, 95% CI=1.45–6.08, P =0.004). Conclusion: In patients with severe aortic stenosis undergoing TAVR, baseline CKD significantly contributes to mortality outcomes at long-term follow up.
No takes yet. Share an insight, caveat, or question.
Al‐Jarallah et al. (2023) conducted an observational in Severe aortic stenosis (n=499). Baseline chronic kidney disease (CKD) vs. No baseline chronic kidney disease (non-CKD) was evaluated on Mortality (p=0.04%). Baseline chronic kidney disease in patients undergoing TAVR was associated with significantly higher mortality compared to non-CKD patients (10% vs. 4.1%; P=0.04%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: